Gene test may spare breast cancer patients unnecessary radiation
NCT ID NCT04069884
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 27 times
Summary
This study is testing whether a genetic test called RecurIndex can identify breast cancer patients with cancer in their lymph nodes who are at low risk of recurrence. If the test shows high risk, patients will receive extra radiation to the lymph nodes; if low risk, they may avoid it. The goal is to see if skipping this radiation is safe and reduces side effects without increasing the chance of cancer coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, 510120, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
regional nodal irradiation (radiation therapy)
What this could lead to
If successful, this could allow many breast cancer patients with low-risk genetics to avoid unnecessary radiation to the lymph nodes, reducing side effects while keeping the same cancer control.
What could go wrong
This is a mid-stage study (Phase NA) with 540 participants, so results are not yet proven. The genetic test may not accurately identify who can safely skip radiation, potentially increasing the risk of cancer recurrence.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.